Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.8661
-0.0310 (-3.46%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Werewolf Therapeutics Revenue
In the year 2024, Werewolf Therapeutics had annual revenue of $1.89M, down -90.55%.
Revenue (ttm)
$1.89M
Revenue Growth
-90.55%
P/S Ratio
20.48
Revenue / Employee
$40,978
Employees
46
Market Cap
39.93M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
HOWL News
- 9 days ago - Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer - GlobeNewsWire
- 26 days ago - Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook - GlobeNewsWire
- 5 months ago - Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - GlobeNewsWire
- 6 months ago - Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire